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Abstract: Chronic sun exposure leads to photodamage, which is characterized clinically by ﬁ  ne 
and coarse wrinkles, dyspigmentation, telangiectasia, laxity, roughness and a sallow appearance. 
Many treatments claim to reduce the signs of photodamage, however evidence from random-
ized controlled trials (RCT) to support these claims is limited. The use of topical retinoids, 
particularly tretinoin, isotretinoin and tazarotene, has been shown to signiﬁ  cantly reduce signs 
of photodamage both clinically and histologically. Over recent years a number of RCTs, have 
afﬁ  rmed that topical tazarotene is an effective and safe treatment for photodamaged skin.
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Chronic or repeated exposure to sunlight light leads to photodamage, which is manifest 
clinically by ﬁ  ne and coarse wrinkles, increased tactile roughness, laxity, dyspigmen-
tation, sallowness and telangiectasia (Yaar and Gilchrest 1990). Histological changes 
include epidermal atrophy, increased melanogenesis, degeneration and disorganization 
of dermal collagen and ﬁ  brillin and deposition of abnormal elastic tissue (Hadshiew 
et al 2000; El-Domyati et al 2002)
Topical retinoids are one of the few interventions to have RCT evidence for 
ability to reduce clinical and histological signs of photodamage: for example regular 
application of topical tretinoin can reduce ﬁ  ne wrinkles, dyspigmentation and tactile 
roughness, accompanied by histological evidence of repair of dermal extracellular 
matrix (Kang, Bergﬁ  eld et al 2005; Samuel et al 2005). Based on available evidence 
the US Food and Drug Administration have approved 0.05% and 0.02% tretinoin 
emollient creams, and 0.1% tazarotene cream for the treatment of photodamage 
(Kang et al 2005).
Retinoids can affect gene transcription both directly and indirectly for example 
by acting directly on genes that contain retinoid response elements, or indirectly 
by inhibiting transcription. They induce their effects mainly through binding to 
and activation of two families of nuclear retinoid receptors: retinoic acid receptor 
(RAR) and retinoid X receptor (RXR). Each family has 3 receptor subtypes: α, β, 
and γ. Receptor selective retinoids have been developed with the aim of maximal 
efﬁ  cacy with minimal adverse effects. Tazarotene is a synthetic receptor selective 
retinoid, whose active metabolite, tazarotenic acid, binds selectively to RAR β and γ 
(Chandraratna 1996).
This review article assesses the evidence for the efﬁ  cacy of topical tazarotene in the 
treatment of photodamaged skin. Publications were identiﬁ  ed by searching Medline, 
Ovid, and the Cochrane Library Databases for the terms “tazarotene”, “photoaging” 
and “photodamage”. All RCTs reporting clinically relevant outcomes were included 
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Clinical response to tazarotene
A pilot study supported by Allergan Inc, Irvine, Ca, USA 
of 10 female volunteers aged between 45 and 65 years with 
moderately photodamaged skin, used a randomized double-
blind within patient comparison to compare the effects of 
tazarotene 0.1% gel applied to one photodamaged forearm 
versus placebo to the opposite arm once daily for 12 weeks 
(Sefton et al 2000). Outcome measures included changes 
in erythema, roughness, laxity, mottling, skin thickness 
and transepidermal water loss (TEWL). Skin biopsies were 
taken at weeks 0 and 12 from both forearms. Tazarotene gel 
as compared to vehicle gel resulted in signiﬁ  cant (p   0.05) 
improvement of skin smoothness as measured by changes 
in surface topography captured by silicone replicas taken at 
the start and the end of the 12-week study period. Although 
there was no detectable difference in skin thickness on ultra-
sound, histological analysis showed a signiﬁ  cant increase 
in epidermal thickness with tazarotene treatment compared 
with vehicle (mean increases of 90% and 14%, respectively 
p = 0.008). TEWL, hygroscopity and water holding capac-
ity were all signiﬁ  cantly increased by tazarotene compared 
with vehicle. Overall histological analysis showed at least 
moderate improvement in 7 of 9 participants on the tazaro-
tene treated side only (1 subject dropped out of the study, 
although no reason is given for this) based on evaluation of 
several changes including acanthosis (thickened epidermis), 
hyperplastic keratinocytes, correction of keratinocyte atypia 
and widened intercellular spaces due to an accumulation of 
hyaluronic acid. All subjects experienced local side effects 
on the tazarotene treated forearm including erythema (all 
of which resolved within 2 weeks) leading to difﬁ  culty in 
maintaining the study blind.
In order to further investigate the use of tazarotene in 
photodamaged skin, Kang et al conducted a larger multi-
center randomized double-blind vehicle-controlled parallel 
comparison of 0.01%, 0.025%, 0.05% and 0.1% tazarotene 
Table1 Summary of trials investigating use of topical tazarotene in the treatment of photodamaged skin
Trial  Study design  N  Intervention  Main outcome measures
Sefton et al  Randomized, double-  10  Tazarotene 0.1% gel applied   Roughness, mottled 
2000  blind within patient     daily to one forearm, placebo   hyperpigmentation, laxity
  comparison    to opposite arm for 12 weeks  
Kang et al   Randomized,   349  0.01%, 0.025%, 0.05%, 0.1%   OIA, global response, mottled 
2001  investigator-masked,     tazarotene creams versus   hyperpigmentation, lentigines, 
  vehicle-controlled     vehicle and 0.05% tretinoin   ﬁ  ne and coarse wrinkles, 
  parallel comparison    emollient cream applied daily   melasma, elastosis, irregular 
      to facial skin for 24 weeks  dyspigmentation, tactile 
        roughness, pore size, 
        telangiectasia, actinic keratoses
Phillips et al   Randomized, double-  563  Tazarotene 0.1% cream versus   Fine wrinkling and mottled 
2002  blind, vehicle-    vehicle applied daily to facial skin  hyperpigmentation
  controlled, parallel     for 24 weeks, followed by  
  comparison followed     tazarotene 0.1% cream daily for 
  by open-label extension    28 weeks for all continuing patients 
Lowe et al   Randomized, double   173  Tazarotene 0.1% cream versus   Incidence of subjects achieving 
2004  blind, parallel     0.05% tretinoin emollient    50% global improvement 
  comparison of two     cream applied daily to facial  
  treatments    skin for 24 weeks 
Machtinger et al  Randomized, double-  50  Tazarotene 0.1% cream versus   Histological assessment for 
2004  blind, vehicle-controlled    vehicle applied daily to facial   keratinocytic and melanocytic 
  parallel comparison    skin for 24 weeks  atypia
      
Kang, Krueger et al   Randomized, double-  568  Tazarotene 0.1% cream versus   Fine wrinkling and mottled 
2005  blind, vehicle-     vehicle cream applied once daily  hyperpigmentation
  controlled     to facial skin for 24 weeks 
Lowe et al   Randomized double-  131  Tazarotene 0.1% cream versus   OIA, global response, mottled 
2006  blind comparison    tazarotene 0.1% cream plus   hyperpigmentation, lentigines, 
      4% hydroquinone cream to   ﬁ  ne and coarse wrinkles, 
      facial skin for 24 weeks  melasma, elastosis, irregular 
        dyspigmentation, tactile roughness
Abbreviations: OIA, overall integrated assessment of photodamage; N, number.Clinical Interventions in Aging 2008:3(1) 73
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creams against 0.05% tretinoin emollient cream and vehicle 
cream applied once daily for 24 weeks (Kang et al 2001). 
Allergan Inc. funded the study of 349 volunteers aged 18 
years or over with moderate facial photodamage as based on 
a 6-point scale at baseline using a photonumeric guideline 
(0 indicates no photodamage; 3, moderate photodamage; 
5 very severe photodamage). The topical treatments were 
applied once daily in the evening. Thirty- seven subjects 
did not complete the study-11 discontinued due to adverse 
events, however analysis was via intention to treat. Clinical 
outcome measures included overall assessment of pho-
todamage (using the 6-point scale), global response to 
treatment (on a 7 point scale where 0 indicates complete 
response; 3 indicates moderate response and; 6, condition 
worsened) and assessment of the following individual 
characteristics: ﬁ  ne wrinkling, mottled hyperpigmentation, 
lentigines, coarse wrinkling, tactile roughness, irregular 
depigmentation, pore size, elastosis, actinic keratoses, and 
telangiectasia. Subjects were also asked to perform a self-
assessment of their response to treatment and whether they 
would continue to use the study medication. Histological 
features were assessed on samples taken from 31 subjects 
at baseline and week 24, and skin surface proﬁ  lometry 
replicas of the crow’s feet area were taken from 53 subjects 
(8 or 9 per group) pre- and post-treatment and assessed by 
computer assisted image analysis.
At week 24 the proportion of subjects with a signiﬁ  cant 
improvement in ﬁ  ne wrinkling (at least 1 grade better com-
pared with baseline) was signiﬁ  cantly higher in all retinoid 
treatment groups, (apart from 0.025% tazarotene which 
became signiﬁ  cant at the week 26 post treatment evalu-
ation) compared with vehicle (p   0.002). Amelioration 
of mottled hyperpigmentation compared to vehicle was 
only signiﬁ  cant in the 0.05% tretinoin and 0.1% tazaro-
tene cream groups. Overall global response to treatment 
(at least 1 grade improved from baseline) was 67% with 
0.1% tazarotene, 52% with 0.05% tazarotene, 41% with 
0.01% tazarotene, 55% with 0.05% tretinoin and 22% 
with vehicle. Histological analysis post-treatment showed 
signiﬁ  cant increased epidermal thickening compared with 
baseline in all retinoid groups, although this was not sig-
niﬁ  cant when compared with vehicle. All retinoids reduced 
melanin content but did not result in signiﬁ  cant changes in 
cellular atypia, dermal elastosis, or type 1 collagen. Opti-
cal proﬁ  lometry of skin surface replicas did not yield any 
signiﬁ  cant results.
Treatment-related adverse events were generally mild 
to moderate, and included erythema, skin irritation and 
desquamation. Self-assessment showed 0.1% tazarotene 
and 0.05% tretinoin creams were favored over vehicle in 
evaluation of treatment response.
A further multicentre randomized study of the efﬁ  cacy 
of once daily 0.1% tazarotene cream applied to the face 
compared with vehicle also conﬁ  rmed the beneﬁ  cial effects 
of tazarotene in treating the signs of photodamage (again 
funding for the study was provided by Allergan Inc) (Phil-
lips et al 2002) . The study consisted of a 24-week period 
where subjects were randomized to 0.1% tazarotene cream 
or vehicle followed by a 28-week open-label extension where 
all subjects received tazarotene. Eighty six percent of the 563 
subjects enrolled completed both phases of the trial with 20 
of the 283 tazarotene treated patients discontinuing due to 
adverse effects in the double-blind phase. Subjects included 
were aged over 18 years, skin phototypes I, II, III or IV with 
at least mild severity of ﬁ  ne wrinkling and mottled hyper-
pigmentation and at least moderate severity of one of these. 
The main outcome measures were ﬁ  ne wrinkling and mottled 
hyperpigmentation and also included overall assessment of 
photodamage, global response to treatment and patient’s 
assessment of photodamage. It is not stated whether analysis 
was based on intention to treat.
As in the previous study a 5-point scale was used to 
assess ﬁ  ne wrinkling, mottled hyperpigmentation, lentigines, 
elastosis, irregular pigmentation, tactile roughness, coarse 
wrinkling and telangiectasia, a 6-point scale was used to 
assess overall photodamage and a 7-point scale global 
improvement. Tazarotene resulted in a signiﬁ  cantly greater 
incidence of clinical improvement (at least 1 grade) in both 
ﬁ  ne wrinkling (from week 8 onwards) and mottled hyper-
pigmentation (from week 2 onwards) compared with vehicle 
(p   0.01). There was also a signiﬁ  cantly greater incidence 
of patients achieving improvement in lentigines, elastosis, 
pore size, coarse wrinkling, overall assessment of photo-
damage and global improvement in the tazarotene group. 
Telangiectasia and actinic keratoses were not signiﬁ  cantly 
improved. More than 80% of the patients in the tazarotene 
group considered their photodamage at least somewhat 
improved from week 12 onwards compared with less than 
45% of the patients using vehicle. During the open label 
phase there was continued clinical improvement in patients 
previously treated with tazarotene suggesting that in clinical 
practice prolonged treatment periods could yield enhanced 
results. The improvement noted in the vehicle treated group 
may have resulted partly from use of emollients and also from 
the requirement of patients to use a sunscreen and restrict 
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Monitoring of blood levels of tazarotenic acid in 48 
patients who had received tazarotene in both phases of the 
trial showed that mean levels were 0.13 ng/ml: not exceeding 
0.71 ng/ml, and not increasing with duration of treatment 
(endogenous total plasma retinoic acid levels 6.6 ng/ml). 
As expected, adverse events were mainly signs of skin 
irritation.
In order to further compare the effects of tazarotene and 
tretinoin in the treatment of photodamaged skin a multicenter, 
double blind, randomized parallel group study (supported by 
funding from Allergan Inc), evaluated tazarotene 0.1% cream 
and tretinoin 0.05% emollient cream used once daily for 24 
weeks (Lowe et al 2004). Inclusion criteria and outcome 
measures were as for the previous study (inclusion criteria: 
at least mild ﬁ  ne wrinkling and mottled hyperpigmentation, 
and at least moderate levels of one of these). Subjects were 
also instructed to use sunscreen (=SPF 15) at least every 
morning, and analysis was on an intention to treat basis. One 
hundred and ﬁ  fty-seven of 173 subjects enrolled completed 
the study: 3 subjects in the tazarotene group withdrew due 
to adverse events and 2 in the tretinoin group.
The incidence of treatment success, as deﬁ  ned by 50% 
or greater global improvement at the study endpoint, was 
78% in the tazarotene group and 67% in the tretinoin group: 
statistical signiﬁ  cance in favor of tazarotene was achieved 
at 16 weeks only. Other statistically signiﬁ  cant differences 
achieved in favor of tazarotene included improvement in 
mottled hyperpigmentation at weeks 12 and 16 and overall 
assessment at week 16, although by week 24 improvement 
in ﬁ  ne wrinkling was the only variable with a statistically 
signiﬁ  cant difference (p   0.01).
Eighty one percent of subjects in the tazarotene group and 
84% in the tretinoin group reported they would continue to 
use their study medication if they chose to continue treatment 
for photodamage after the study. Adverse events were similar 
to previous studies; the only signiﬁ  cant difference was a 
higher incidence of skin “burning” in the tazarotene group 
in the ﬁ  rst week of treatment.
In 2005 a further randomized, double-blind trial of 
tazarotene 0.1% cream used for 24 weeks to treat facial 
photodamage was published (Kang, Krueger et al 2005). The 
purpose of this study was to conﬁ  rm efﬁ  cacy and tolerability 
of tazarotene. Inclusion criteria were as discussed previ-
ously. Primary outcome measures were again ﬁ  ne wrinkling 
and mottled hyperpigmentation as measured on the 5-point 
scale. Clinically signiﬁ  cant improvement was deﬁ  ned as at 
least a 10% between group difference in the incidence of 
patients with at least a 1-grade improvement from baseline. 
Secondary outcome measures included lentigines, irregular 
depigmentation, elastosis, apparent pore size, tactile rough-
ness, coarse wrinkling, telangiectasia, overall integrated 
assessment of photodamage, and global response to treatment 
(as for the earlier study by Kang et al).
Photographs taken at baseline were used to aid investiga-
tors in evaluating response to treatment. Analysis for clinical 
efﬁ  cacy was based on intention to treat.
Five hundred and ﬁ  ve subjects, of 568 enrolled, com-
pleted the study: 14 discontinued due to adverse events. 63% 
of tazarotene treated subjects achieved clinical improve-
ment in ﬁ  ne wrinkling at week 24 compared with 24% in 
the vehicle group (p   0.001) and 87% vs 43% achieved 
improvement in mottled hyperpigmentation (p   0.001). 
There were also signiﬁ  cantly higher percentages of patients 
achieving clinical improvement in lentigines, irregular dys-
pigmentation, apparent pore size, elastosis, tactile roughness 
and overall integrated assessment. There were no signiﬁ  cant 
between group differences in coarse wrinkling, telangiecta-
sia or actinic keratoses. At week 24, 93% of the tazarotene 
treated subjects considered their photodamage to be at least 
somewhat improved compared to 49% of vehicle treated 
subjects. Adverse events were more common in the active 
treatment group and included burning, desquamation and 
erythema. The authors comment that the reduction in appar-
ent pore size may play an important role in overall patient 
satisfaction. Possible hypotheses to explain this reduction 
include retinoid-induced synthesis of collagen and/or a 
comedolytic affect.
Histological response to tazarotene
Machtinger et al conducted a double-blind randomized 
vehicle controlled trial to determine the histological effects 
of tazarotene 0.1% cream when applied to the face once 
daily for 24 weeks (Machtinger et al 2004). Inclusion 
criteria were the same as for previous studies. Three mil-
limetre punch biopsies were taken from the crow’s feet 
area at weeks 0 and 24. Primary outcome measures were 
improvement in keratinocytic and melanocytic atypia: 
overall assessments were made of cells that appeared 
abnormal in nuclear size, shape, staining characteristics or 
position relative to contiguous cells. Distribution of atypia 
was graded on a 4 point scale: 0, not present; 1, focal; 2 
multifocal; and 3, diffuse. Assessment of epidermal and 
dermal parameters were also made, as were clinical efﬁ  cacy 
measures as in the previous study.
Forty-eight of 50 patients randomized completed the 
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either a reduction or no change in keratinocyte or melanocyte 
atypia compared with vehicle-treated patients (76% vs 50% 
and 80% vs 50% respectively), although the change in 
distribution or severity of keratinocytic atypia just failed to 
reach statistical signiﬁ  cance (p = 0.055). Epidermal oedema, 
absent at baseline, increased signiﬁ  cantly more with tazaro-
tene than with vehicle (p   0.001). Epidermal thickness and 
epidermal polarity scores also increased signiﬁ  cantly in the 
active treatment group (p = 0.005 and p = 0.008 respectively). 
Other measures including epidermal inﬂ  ammation, abnor-
mal elastin, number of epidermal melanocytes and dermal 
melanin did not show signiﬁ  cant between group differences. 
The clinical efﬁ  cacy of tazarotene was demonstrated by sig-
niﬁ  cant improvements (at least 1 grade improvement) in a 
higher percentage of patients than with the vehicle in overall 
assessment, mottled hyperpigmentation, irregular depigmen-
tation, coarse wrinkling, elastosis and tactile roughness. No 
patients discontinued due to adverse events. The authors 
concluded that tazarotene 0.1% cream may help normalize 
cellular changes and thus reduce progression to precancerous 
states: perhaps by expression of the tumor suppressor gene, 
tazarotene inducible gene-3.
Tazarotene in combination therapy
Most recently Lowe et al have studied the efﬁ  cacy of taz-
arotene 0.1% cream versus a combination of tazarotene 
0.1% cream and hydroquinone 4% cream in the treatment 
of photodamaged facial skin (Lowe et al 2006). The trial 
was conducted as a double blind randomized study over a 
24-week period. Inclusion criteria were similar to previ-
ous studies including mottled hyperpigmentation of at 
least moderate severity (on a 5 point scale) and an overall 
integrated assessment (of photodamage) score of at least 
moderate (on a 6 point scale). Patients were divided into two 
groups: tazarotene 0.1% cream in the evening and placebo 
cream each morning or tazarotene cream in the evening with 
hydroquinone 4% cream in the morning. Outcome measures 
included global response to treatment and changes in len-
tigines, mottled hyperpigmentation, irregular dyspigmenta-
tion, melasma, ﬁ  ne wrinkling, coarse wrinkling, elastosis, 
tactile roughness and overall integrated assessment.
One hundred and thirty-one subjects were enrolled in 
the study and 114 completed. Four subjects discontinued 
due to adverse events: two from the tazarotene alone group 
(hyperpigmentation and exacerbation of rosacea), and two 
from the tazarotene plus hydroquinone group (peeling, 
burning, and redness). Signiﬁ  cantly more subjects from 
the tazarotene plus hydroquinone group achieved at least 
50% global improvement at weeks 8 to 16, however by 24 
weeks the results were comparable (88% with tazarotene 
plus hydroquinone versus 76% with tazarotene alone). The 
only other variables in which there were signiﬁ  cant differ-
ences in the incidence of patients achieving at least a 1-grade 
improvement from baseline were lentigines (76% in the 
tazarotene plus hydroquinone group, versus 54% tazarotene 
alone at 24 weeks p   0.01) and mottled hyperpigmentation 
(92% in the tazarotene plus hydroquinone group, versus 
76% tazarotene alone at 16 weeks p   0.05), although by 
24 weeks there was no signiﬁ  cant difference in improvement 
in mottled hyperpigmentation between the two groups. A 
higher proportion of patients reported complete improve-
ment in photodamage with tazarotene plus hydroquinone 
(18% compared to 2% with tazarotene alone) and similar 
numbers reported at least deﬁ  nite improvement (75% versus 
72%). The results from this study suggest that photodamaged 
patients with dyspigmentation may obtain greater clinical 
improvement with the use of hydroquinone in combination 
with the topical retinoid.
Conclusion
Available evidence indicates that in the short term at least 
topical tazarotene is safe and effective for the treatment of 
photodamaged skin. Furthermore, the clinical improvement 
seen in the tazarotene treated groups is consistent between 
the different trials. Adverse effects associated with tazarotene 
are mainly mild to moderate cutaneous irritation, which in 
clinical practice could perhaps be avoided by a more gradual 
institution of treatment.
The longest trial to date suggests that continued clinical 
improvement can occur beyond one year of treatment, and 
further trials to assess optimum duration of therapy and 
appropriate “maintenance” regimes to guide clinical practice 
are warranted.
Summary points
•  Tazarotene is a synthetic retinoid selective for RAR β 
and γ.
•  There is good evidence from RCTs that tazarotene 
improves both the clinical and histological signs of pho-
todamaged skin.
•  Based on the available evidence tazarotene should be used 
once daily in conjunction with a sunscreen (SPF   15) 
for optimum results.
•  Side effects of tazarotene tend to be mild, transient cuta-
neous irritation that may be reduced by a more gradual 
institution of treatment.Clinical Interventions in Aging 2008:3(1) 76
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